Cipla’s Yurpeak Weight-Loss Injectable Drug; Clocks ₹14 Crore in its First Month Across Tier-2/3 Markets

Pharma company Cipla reported strong initial performance for its newly launched anti-obesity drug, Yurpeak, with ₹14 crore worth of sales recorded in its first month.  

The once-weekly injectable is Cipla’s in-licensed version of tirzepatide, focusing on chronic weight management. 

₹14 Crore Sales for Cipla's Yurpeak in December 2025 

According to monthly PharmaTrac data, Cipla's brand Yurpeak achieved net sales of ₹14 crore in December 2025, with approximately 12,000 pre-filled syringes sold.  

The brand was introduced at the innovator’s price level and initially concentrated its distribution in tier-2 and tier-3 cities, where Eli Lilly's innovator brand Mounjaro has limited reach.  

Yurpeak is Cipla’s in-licensed alternate of tirzepatide, developed by Eli Lilly. 

Comparison with Competitor Molecules 

In terms of performance, Yurpeak’s debut sales surpassed those of semaglutide-based Wegovy marketed by Novo Nordisk, which recorded ₹11 crore sales via 10,000 syringes in the same month.  

Mounjaro retained its lead with ₹105 crore in monthly sales, translating to 89,000 units sold. This marked a slight decrease from 98,000 and 1,06,000 units sold in previous cycles.  

Some brands like Poviztra, another semaglutide formulation marketed by Emcure Pharma, are also entering the market and expected to affect competitive dynamics. The Indian anti-obesity drug market, currently valued at ₹1,169 crore, has expanded significantly following the entry of branded GLP-1 and GIP/GLP-1 injectables. 

Read More: Cipla Share Price Falls Nearly 5% After USFDA Flags Compliance Issues at Key Partner! 

Cipla Share Price Performance  

As of January 09, 2026, at 12:13 PM, Cipla share price on NSE was trading at ₹1,462.70 up by 0.14% from the previous closing price. 

Conclusion 

Cipla’s Yurpeak brand made a notable entry into the Indian anti-obesity market with ₹14 crore sales in its launch month of December 2025. Competing directly with established brands like Mounjaro and Wegovy, this launch adds to the dynamic landscape of chronic weight management drugs. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.